NEW YORK—A week after Weber Shandwick Worldwide’s consumer healthcare unit picked up Pfizer’s international Viagra business, the firm announced that it had been selected to provide public relations support for the launch of Pfizer’s Inspra— recently approved by the U.S. Food and Drug Administration for the treatment of congestive heart failure in patients who have had a heart attack—in the United States and Europe.
Weber Shandwick’s healthcare practice in New York will lead the launch program in the U.S. and the agency’s office in London will support the launch in Europe.
Inspra, an aldosterone blocker, works by inhibiting the effects of aldosterone, a hormone that may contribute to the development and progression of hypertension and congestive heart failure, including
damage to blood vessels, kidney and the heart. An estimated five million Americans suffer from CHF, and up to 700,000 new cases are diagnosed each year.
According to Laura Schoen, president of Weber Shandwick’s global healthcare practice, “Key to our public relations program will be an effort to educate multiple constituencies about the drug’s innovative mechanism of action and impact.”